Abstract:Introduction: Phosphatidylinositol 3-kinases (PI3Ks) overexpression can elicit cellular homeostatic dysregulation, which further contributes to tumorigenesis, with PI3Kα emerging as the most prevalent mutant isoform kinase among PI3Ks. Therefore, selective inhibitors targeting PI3Kα have attracted considerable interest in recent years. Molecular hybridization, with the advantage of simplified pharmacokinetics and drug-drug interactions, emerged as one of the important avenues for discovering potential drugs. Objectives: This study aimed to construct PI3Kα inhibitors by hybridization and investigate their antitumor activity and mechanism. Methods: 26 quinazoline-2-indolinone derivatives were obtained by molecular hybridization, and their structure-activity relationship was analyzed by MTT, in vitro kinase activity and molecular docking. The biological evaluation of compound 8 was performed by transwell, flow cytometry, laser scanning confocal microscopy, Western blot, CTESA and immunohistochemistry. Results: Here, we employed molecular hybridization methods to construct a series of quinazoline-2-indolinone derivatives as PI3Kα selective inhibitors. Encouragingly, representative compound 8 exhibited a PI3Kα enzymatic IC50 value of 9.11 nM and 10.41/16.99/37.53-fold relative to the biochemical selectivity for PI3Kβ/γ/δ, respectively. Moreover, compound 8 effectively suppressed the viability of B16, HCT116, MCF-7, H22, PC-3, and A549 cells (IC50 values: 0.2 μM ∼ 0.98 μM), and dramatically inhibited the proliferation and migration of NSCLC cells, as well as induced mitochondrial apoptosis through the PI3K/Akt/mTOR pathway. Importantly, compound 8 demonstrated potent in vivo anti-tumor activity in non-small cell lung cancer mouse models without visible toxicity. Conclusions: This study presented a new avenue for the development of PI3Kα inhibitors and provided a solid foundation for novel QHIDs as potential future therapies for the treatment of NSCLC.

Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.

Synthesis and Antitumor Activity Evaluation of 4,6-Disubstituted Quinazoline Derivatives As Novel Pi3k Inhibitors

Synthesis and Antitumor Activity Evaluation of PI3K Inhibitors Containing 3-Substituted Quinazolin-4(3H)-one Moiety

Discovery of 2-Methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or Quinolin-6-yl)benzamides As Novel PI3K Inhibitors and Anticancer Agents by Bioisostere.

Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.

Synthesis and Biological Evaluation of Novel 2-Arylamino-3-(arylsulfonyl)quinoxalines As PI3Kα Inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Discovery of Novel 2-Piperidinol-3-(arylsulfonyl)quinoxalines As Phosphoinositide 3-Kinase Α (pi3kα) Inhibitors

Novel 4-Acrylamido-quinoline Derivatives As Potent PI3K/mTOR Dual Inhibitors: the Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.

Novel 6-Aryl Substituted 4-Pyrrolidineaminoquinazoline Derivatives As Potent Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitors.

Conformationally Restricted Quinazolone Derivatives As PI3Kδ-selective Inhibitors: the Design, Synthesis and Biological Evaluation.

Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives As Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives As Potential PI3Kδ Inhibitors

Introduction of Pyrrolidineoxy or Piperidineamino Group at the 4-Position of Quinazoline Leading to Novel Quinazoline-Based Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitors.